CStone Pharmaceuticals (CSPHF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CStone Pharmaceuticals (CSPHF) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. La acción obtiene una puntuación de 50/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 17 mar 2026CStone Pharmaceuticals (CSPHF) Resumen de Asistencia Médica y Tuberías
CStone Pharmaceuticals is a biopharmaceutical company focused on immuno-oncology and precision medicines for cancer patients in China and internationally. With a pipeline of novel therapies and strategic collaborations, CStone aims to address unmet medical needs, although it currently operates with negative profit margins in a competitive market.
Tesis de Inversión
CStone Pharmaceuticals presents a compelling, albeit high-risk, investment thesis centered on its innovative pipeline of immuno-oncology and precision medicine assets. The company's focus on addressing unmet medical needs in the oncology space, particularly in China, offers significant growth potential. Key value drivers include the successful commercialization of Sugemalimab and GAVRETO, as well as the advancement of its pipeline assets like Nofazinlimab and Fisogatinib. The company's current market capitalization of $1.26 billion reflects investor expectations for future growth, but its negative profit margin of -136.1% underscores the challenges it faces in achieving profitability. Upcoming clinical trial results and regulatory approvals will serve as key catalysts. However, potential risks include competition from established pharmaceutical companies and the inherent uncertainties in drug development.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap of $1.26 billion indicates investor confidence in CStone's pipeline and future growth potential.
- Negative P/E ratio of -33.21 reflects the company's current lack of profitability due to ongoing R&D investments.
- Gross Margin of 12.2% indicates the profitability of CStone's current product sales after accounting for the cost of goods sold.
- Beta of 0.61 suggests that the stock is less volatile than the overall market.
- The company's focus on immuno-oncology and precision medicines positions it in a high-growth area of the pharmaceutical industry.
Competidores y Pares
Fortalezas
- Innovative drug pipeline targeting unmet medical needs in oncology.
- Strategic focus on the Chinese market with significant growth potential.
- Established partnerships with leading pharmaceutical companies.
- Experienced management team with expertise in drug development and commercialization.
Debilidades
- Negative profit margin and reliance on external funding.
- Limited commercial track record compared to established pharmaceutical companies.
- High R&D expenses and long drug development timelines.
- Dependence on regulatory approvals for drug commercialization.
Catalizadores
- Upcoming: Clinical trial results for Nofazinlimab in hepatocellular carcinoma expected in 2026.
- Upcoming: Potential regulatory approval for Sugemalimab in additional cancer indications by 2027.
- Ongoing: Expansion of commercial operations in China and international markets.
- Ongoing: Strategic partnerships and licensing agreements to expand the drug pipeline.
- Ongoing: Development and advancement of novel immuno-oncology and precision medicine assets.
Riesgos
- Potential: Competition from established pharmaceutical companies with larger resources.
- Potential: Uncertainties in clinical trial outcomes and regulatory approvals.
- Ongoing: Pricing pressures and reimbursement challenges in the Chinese market.
- Potential: Intellectual property disputes and patent expirations.
- Ongoing: Negative profit margin and reliance on external funding.
Oportunidades de crecimiento
- Expansion of Sugemalimab's Indications: Sugemalimab, CStone's anti-PD-L1 antibody, has the potential for expanded use across multiple cancer types. Securing regulatory approvals for additional indications, such as non-small cell lung cancer and gastric cancer, could significantly increase its market reach. The global market for PD-L1 inhibitors is substantial, offering a considerable revenue opportunity for CStone. Timeline: Ongoing clinical trials and regulatory submissions expected through 2027.
- Advancement of Nofazinlimab for Hepatocellular Carcinoma: Nofazinlimab, a PD-1 antibody, targets hepatocellular carcinoma (HCC), a prevalent cancer in China and globally. Positive clinical trial results and subsequent regulatory approval could establish Nofazinlimab as a key treatment option for HCC patients. The HCC market is expected to grow, driven by increasing incidence and limited treatment options. Timeline: Clinical trial data expected in 2026, with potential regulatory submission in 2027.
- Commercialization of Fisogatinib for FGFR4-Driven Cancers: Fisogatinib, an FGFR4 inhibitor, targets cancers driven by FGFR4 mutations, including hepatocellular carcinoma. Successful clinical development and commercialization could provide a targeted therapy for a specific subset of cancer patients. The market for FGFR inhibitors is emerging, offering a first-in-class opportunity for CStone. Timeline: Ongoing clinical trials with potential for accelerated approval pathways.
- Strategic Partnerships and Licensing Agreements: CStone can leverage strategic partnerships and licensing agreements to expand its pipeline and geographic reach. Collaborating with other pharmaceutical companies or research institutions can accelerate drug development and commercialization efforts. Licensing agreements can provide access to novel technologies and therapies. Timeline: Ongoing business development activities with potential for near-term announcements.
- Expansion into New Geographic Markets: While CStone is primarily focused on the Chinese market, expanding into other geographic regions, such as Southeast Asia or Europe, could drive future growth. Securing regulatory approvals and establishing commercial operations in new markets would require significant investment but could unlock substantial revenue opportunities. Timeline: Long-term strategic goal with potential for initial expansion efforts in 2028-2030.
Oportunidades
- Expansion of existing drug indications to increase market reach.
- Advancement of pipeline assets to address additional cancer types.
- Strategic partnerships and licensing agreements to expand pipeline and geographic reach.
- Entry into new geographic markets beyond China.
Amenazas
- Competition from established pharmaceutical companies with larger resources.
- Uncertainties in clinical trial outcomes and regulatory approvals.
- Pricing pressures and reimbursement challenges in the Chinese market.
- Intellectual property disputes and patent expirations.
Ventajas competitivas
- Proprietary drug pipeline with novel immuno-oncology and precision medicine assets.
- Strong research and development capabilities.
- Strategic partnerships with leading pharmaceutical companies.
- Established presence in the Chinese oncology market.
- Intellectual property protection for key drug candidates.
Acerca de CSPHF
CStone Pharmaceuticals, established in 2015 and headquartered in Shanghai, China, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative immuno-oncology and precision medicines. The company's mission is to address the unmet medical needs of cancer patients both in China and globally. CStone's portfolio includes Sugemalimab, a monoclonal antibody against programmed death ligand 1 (PD-L1); GAVRETO, an RET inhibitor used in the treatment of advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor targeted at adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. Beyond its currently marketed products, CStone Pharmaceuticals has a robust pipeline of drug candidates, including Nofazinlimab, a PD-1 antibody for hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor for relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor for hepatocellular carcinoma. The company is also developing several other compounds, such as CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors, as well as CS5001 for both solid tumors and hematologic malignancies. CStone operates in a highly competitive biotechnology landscape, focusing on innovative therapies for cancer treatment.
Qué hacen
- Researches and develops immuno-oncology drugs.
- Develops precision medicines for cancer treatment.
- Commercializes oncology drugs in China and internationally.
- Focuses on addressing unmet medical needs in cancer care.
- Offers Sugemalimab, a PD-L1 antibody.
- Provides GAVRETO, an RET inhibitor for thyroid cancers.
- Develops avapritinib, a KIT/PDGFRA inhibitor for gastrointestinal stromal tumors.
Modelo de Negocio
- Develops and patents novel oncology drugs.
- Conducts clinical trials to demonstrate drug efficacy and safety.
- Obtains regulatory approvals for drug commercialization.
- Manufactures and markets approved drugs.
- Generates revenue through drug sales.
Contexto de la Industria
CStone Pharmaceuticals operates within the rapidly evolving biotechnology industry, specifically targeting the oncology market. The global oncology market is projected to reach hundreds of billions of dollars by 2026, driven by an aging population and increasing cancer incidence. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, such as ASCLF (Ascentage Pharma), CHIZF (Chi-Med), CSBTF (Connect Biopharma), MEOBF (Meihua International Medical Technologies), and NURPF (Nurexone Biologic). CStone differentiates itself through its focus on innovative therapies and its strategic presence in the Chinese market.
Clientes Clave
- Cancer patients in China and internationally.
- Hospitals and oncology clinics.
- Healthcare providers prescribing cancer treatments.
- Government healthcare systems.
- Private insurance companies.
Finanzas
Gráfico e información
Precio de la acción de CStone Pharmaceuticals (CSPHF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para CSPHF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CSPHF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para CSPHF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de CSPHF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Jianxin Yang
CEO
Jianxin Yang serves as the CEO of CStone Pharmaceuticals, leading a team of 135 employees. His background includes extensive experience in the pharmaceutical industry, with a focus on drug development and commercialization. He has held leadership positions at several multinational pharmaceutical companies, where he oversaw the development and launch of multiple oncology drugs. Yang's expertise spans clinical research, regulatory affairs, and market access.
Historial: Under Jianxin Yang's leadership, CStone Pharmaceuticals has advanced its pipeline of immuno-oncology and precision medicine assets, securing regulatory approvals for key drugs like Sugemalimab and GAVRETO. He has also overseen strategic partnerships and licensing agreements to expand the company's portfolio. Yang's focus on innovation and commercial execution has driven CStone's growth in the competitive oncology market.
Información del mercado OTC de CSPHF
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market, indicating that CStone Pharmaceuticals (CSPHF) may not meet the minimum financial or disclosure requirements for higher OTC tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and liquidity.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity compared to major exchanges.
- Potential for price volatility and manipulation.
- Increased risk of fraud or misrepresentation.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and regulatory filings.
- Assess the company's management team and track record.
- Evaluate the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established partnerships with reputable pharmaceutical companies.
- Progress in clinical trials and regulatory approvals for key drugs.
- Experienced management team with expertise in the pharmaceutical industry.
- Focus on addressing unmet medical needs in oncology.
- Presence in the Chinese market with significant growth potential.
Preguntas Comunes Sobre CSPHF
¿Cuáles son los factores clave para evaluar CSPHF?
CStone Pharmaceuticals (CSPHF) actualmente tiene una puntuación IA de 50/100, indicando puntuación moderada. Fortaleza clave: Innovative drug pipeline targeting unmet medical needs in oncology.. Riesgo principal a monitorear: Potential: Competition from established pharmaceutical companies with larger resources.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de CSPHF?
CSPHF actualmente puntúa 50/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de CSPHF?
Los precios de CSPHF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre CSPHF?
La cobertura de analistas para CSPHF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en CSPHF?
Las categorías de riesgo para CSPHF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from established pharmaceutical companies with larger resources.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de CSPHF?
La relación P/E para CSPHF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está CSPHF sobrevalorada o infravalorada?
Determinar si CStone Pharmaceuticals (CSPHF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de CSPHF?
CStone Pharmaceuticals (CSPHF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on provided data and may be subject to change.
- OTC market data may have limited availability and accuracy.